you're kidding right? You just stated what I stated in my last post. I gave you a valuation on what a successful flu drug would bring based on current drugs in the market. That's a valuation (as you even state) based on FDA approval. I clearly stipulated "if it works in humans". That value as stated is obviously just as valid today as it was when I wrote the post, as anybody in the industry would tell you. Look around the biotech/drug discovery industry, 5x sales is conservative. The question is not what the value of such a drug would be but whether NNVC can successfully produce it (and within a reasonable timeframe). Pegging a valuation on a successful flu drug is a far cry from a prediction on stock price. Thanks for proving my point.